Non-Dilutive Funding

Edgewater Wireless (TSXV: YFI, OTC: KPIFF) reported Q1 FY2026 results, highlighting progress in Spectrum Slicing™ technology and securing $921,000 in non-dilutive funding. Key achievements include showcasing Spectrum Slicing, completing RF front-end packaging, and prototyping an AI subsystem. The company extended the maturity of convertible debentures to 2027 for enhanced financial flexibility. A net loss of $359,956 was reported with a working capital deficiency. Focus remains on commercializing Spectrum Slicing through silicon/IP licensing and securing partnerships, while addressing challenges in a competitive market.

Genflow Biosciences (GENFF) secured a €4 million non-dilutive grant from Belgium’s Wallonia Region to advance GF-1002, its gene therapy candidate for Metabolic Associated Steatohepatitis (MASH). The grant covers a three-year development program aligned with Genflow’s clinical roadmap. While initial disbursement awaits administrative procedures, the GF-1002 program continues without interruption. Genflow highlights that all project-related expenses incurred in 2025 will be eligible under the grant’s terms.